Literature DB >> 25114074

Optimizing regions-of-interest composites for capturing treatment effects on brain amyloid in clinical trials.

Volha Tryputsen1, Allitia DiBernardo1, Mahesh Samtani1, Gerald P Novak1, Vaibhav A Narayan1, Nandini Raghavan1.   

Abstract

BACKGROUND: Pittsburgh Compound B (PiB) positron emission tomography (PET) neuroimaging is a powerful research tool to characterize amyloid evolution in the brain. Quantification of amyloid load critically depends on (i) the choice of a reference region (RR) and (ii) on the selection of regions of interest (ROIs) to derive the standard uptake value ratios (SUVRs).
OBJECTIVE: To evaluate the stability, i.e., negligible amyloid accumulation over time, of different RRs, and the performance of different PiB summary measures defined by selected ROIs and RRs for their sensitivity to detecting longitudinal change in amyloid burden.
METHODS: To evaluate RRs, cross-sectional and longitudinal analyses of focal regional and composite measures of amyloid accumulation were carried out on the standardized PiB-PET regional data for cerebellar grey matter (CER), subcortical white matter (SWM), and pons (PON). RRs and candidate composite SUVR measures were further evaluated to select regions and develop novel composites, using standardized 2-year change from baseline.
RESULTS: Longitudinal trajectories of PiB4-average of anterior cingulate (ACG), frontal cortex (FRC), parietal cortex, and precuneus-demonstrated marked variability and small change from baseline when normalized to CER, larger changes and less variability when normalized to SWM, which was further enhanced for the composite in PON-normalized settings. Novel composite PiB3, comprised of the average SUVRs of lateral temporal cortex, ACG, and FRC was created.
CONCLUSION: PON and SWM appeared to be more stable RRs than the CER. PiB3 showed compelling sample size reduction and gains in power calculations for clinical trials over conventional PiB4 composite.

Entities:  

Keywords:  ${11}^C$-PiB; Alzheimer's disease; amyloid imaging; brain; pons

Mesh:

Substances:

Year:  2015        PMID: 25114074     DOI: 10.3233/JAD-131979

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

1.  Amyloid Load: A More Sensitive Biomarker for Amyloid Imaging.

Authors:  Alex Whittington; Roger N Gunn
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

2.  Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.

Authors:  Sepideh Shokouhi; Desmond Campbell; Aaron B Brill; Harry E Gwirtsman
Journal:  Brain Pathol       Date:  2016-09       Impact factor: 6.508

3.  Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.

Authors:  Susan M Landau; Allison Fero; Suzanne L Baker; Robert Koeppe; Mark Mintun; Kewei Chen; Eric M Reiman; William J Jagust
Journal:  J Nucl Med       Date:  2015-03-05       Impact factor: 10.057

4.  Amyloid accumulation in Down syndrome measured with amyloid load.

Authors:  Matthew D Zammit; Charles M Laymon; Tobey J Betthauser; Karly A Cody; Dana L Tudorascu; Davneet S Minhas; Marwan N Sabbagh; Sterling C Johnson; Shahid H Zaman; Chester A Mathis; William E Klunk; Benjamin L Handen; Ann D Cohen; Bradley T Christian
Journal:  Alzheimers Dement (Amst)       Date:  2020-04-16

5.  PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.

Authors:  Matthew D Zammit; Dana L Tudorascu; Charles M Laymon; Sigan L Hartley; Shahid H Zaman; Beau M Ances; Sterling C Johnson; Charles K Stone; Chester A Mathis; William E Klunk; Ann D Cohen; Benjamin L Handen; Bradley T Christian
Journal:  Neuroimage       Date:  2021-01-07       Impact factor: 6.556

6.  Identifying Mild Alzheimer's Disease With First 30-Min 11C-PiB PET Scan.

Authors:  Chushu Shen; Zhenguo Wang; Hongzhao Chen; Yan Bai; Xiaochen Li; Dong Liang; Xin Liu; Hairong Zheng; Meiyun Wang; Yongfeng Yang; Haifeng Wang; Tao Sun
Journal:  Front Aging Neurosci       Date:  2022-04-05       Impact factor: 5.702

Review 7.  Quantification of amyloid PET for future clinical use: a state-of-the-art review.

Authors:  Hugh G Pemberton; Lyduine E Collij; Fiona Heeman; Ariane Bollack; Mahnaz Shekari; Gemma Salvadó; Isadora Lopes Alves; David Vallez Garcia; Mark Battle; Christopher Buckley; Andrew W Stephens; Santiago Bullich; Valentina Garibotto; Frederik Barkhof; Juan Domingo Gispert; Gill Farrar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-07       Impact factor: 10.057

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.